Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
-
Wondering if Minimed Group at around US$14.01 is pricing in too much hope or not enough? This article walks through the numbers so you can judge the value story for yourself.
-
The stock has seen a 3.2% decline over the last 7 days and a 24.2% decline year to date, which can change how the market views both its potential and its risks.
-
Recent coverage of Minimed Group has focused on its position within the healthcare sector and how sentiment around medical equipment names has shifted. This helps frame these price moves. Broader market commentary has also highlighted how investors are reassessing risk in growth oriented healthcare names, and Minimed Group has been part of that conversation.
-
Minimed Group currently holds a 5 out of 6 valuation score . The sections that follow will compare traditional valuation checks with alternative ways to think about what the market is really pricing in today.
Approach 1: Minimed Group Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model takes estimates of the cash a business might generate in the future and discounts those amounts back to today using a required rate of return. The goal is to translate those future cash flows into a single estimate of what the equity could be worth right now.
For Minimed Group, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is a loss of $188.30 million. Analyst inputs and subsequent extrapolations then project free cash flow moving to $641 million in 2030, with interim years such as 2026 at a $177.40 million loss and 2028 at $245.50 million.
After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $60.25 per share. Compared with the recent share price of around $14.01, this implies a 76.7% discount, which indicates that Minimed Group is trading well below this cash flow based estimate.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Minimed Group is undervalued by 76.7%. Track this in your watchlist or portfolio , or discover 59 more high quality undervalued stocks .
Approach 2: Minimed Group Price vs Sales
For companies where earnings are not yet a steady guide, the P/S ratio is often a practical way to think about value because it ties the share price to current revenue rather than profits that can swing around with investment and accounting choices.
Growth expectations and risk still matter here. Investors usually pay a higher P/S multiple when they expect stronger, more reliable revenue growth and accept a lower multiple when the outlook or risk profile is less certain.
Minimed Group currently trades on a P/S ratio of 1.36x. This sits below the Medical Equipment industry average P/S of 2.61x and also below the peer average of 2.10x, which suggests the market is assigning a lower value to each dollar of Minimed Group's sales compared with many comparable names.
Simply Wall St uses a proprietary “Fair Ratio” for P/S, which reflects what multiple might be reasonable after considering factors such as earnings growth, profit margins, industry, market cap and company specific risks. This tends to give a more tailored view than simple peer or industry comparisons because it adjusts for differences in quality and risk rather than assuming all companies deserve the same multiple.
There is currently no Fair Ratio available for Minimed Group, so the P/S comparison can highlight how the stock sits against its sector, but it does not support a firm overvalued or undervalued judgment using this method alone.
Result: ABOUT RIGHT
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies .
Upgrade Your Decision Making: Choose your Minimed Group Narrative
Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in: a simple way for you to attach a clear story about Minimed Group to your numbers, including your own fair value, revenue, earnings and margin assumptions.
A Narrative connects three things: what you believe about the business, the financial forecast that follows from that view, and the fair value that results from those assumptions. This allows you to see whether the price around US$14.01 aligns with your story or not.
Narratives on Simply Wall St, available to millions of investors on each company’s Community page, update automatically when fresh information such as news or earnings is released. This means your fair value and the gap between Fair Value and Price can help you decide if Minimed Group looks attractive, fully priced or less attractive at any given time.
For example, one Minimed Group Narrative might assume relatively cautious margins and arrive at a fair value close to the current price. Another might assume stronger long term economics and arrive at a fair value closer to the DCF estimate of about US$60.25, showing how different investors can reasonably reach very different conclusions using the same tool.
Do you think there's more to the story for Minimed Group? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MMED .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
